# Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer

> **NCT03455452** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 600 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Renal Cell Cancer
- Adenocarcinoma Of Kidney
- Adenocarcinoma, Renal Cell
- Kidney Cancer
- Cancer of the Kidney

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03455452
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-21
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455452, "Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03455452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*